⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569627 | 0.93 | — | — | |
| SCHEMBL3988214 | 0.70 | NPC1 (0.35) | — | |
| SCHEMBL2942689 | 0.70 | NPC1 (0.35) | — | |
| SCHEMBL3993781 | 0.70 | NPC1 (0.35) | — | |
| SCHEMBL4141096 | 0.69 | POLB (0.33) | — | |
| SCHEMBL846506 | 0.69 | TNKS2 (0.32) | — | |
| SCHEMBL15523280 | 0.69 | HTR2C (0.32) | — | |
| SCHEMBL845578 | 0.69 | PDK1 (0.30) | — | |
| SCHEMBL2284635 | 0.67 | — | — | |
| SCHEMBL13444 | 0.67 | NPC1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074115-B1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2018-03-07 | — | — | EP | claimed |
| US-9650391-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS INC. (US) | 2017-05-16 | — | — | US | claimed |
| EP-2074115-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | claimed |
| WO-2008083354-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | claimed |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| EP-4132652-A1 | AXL INHIBITORS FOR ANTIVIRAL THERAPY | BerGenBio ASA (NO) | 2023-02-15 | — | — | EP | disclosed |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | BERGENBIO ASA (NO) | 2022-12-27 | — | — | US | disclosed |
| EP-3131897-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20070225318-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | BIOLIPOX AB (SE) | 2007-09-27 | — | — | US | disclosed |
| EP-1794145-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-06-13 | — | — | EP | disclosed |
| US-20060142324-A1 | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands | NEUROGEN CORPORATION | 2006-06-29 | — | — | US | disclosed |
| US-7037922-B1 | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands | NEUROGEN CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2006032851-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| EP-1165555-B1 | ARYL FUSED 2,4-DISUBSTITUTED PYRIDINES: NK3 RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1165555-A2 | ARYL FUSED 2,4-DISUBSTITUTED PYRIDINES: NK3 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058307-A2 | ARYL FUSED 2,4-DISUBSTITUTED PYRIDINES: NK3 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |